chemotherapy + bevacizumab + adebrelimab

This is a **multi-agent combination regimen** used or under development for the treatment of various cancers, typically combining three components: - **Chemotherapy**: Refers to the use of cytotoxic anticancer drugs (such as 5-fluorouracil, irinotecan, paclitaxel, cisplatin, carboplatin, etc.). The specific agents depend on the cancer type and treatment protocol. - **Bevacizumab**: A recombinant humanized monoclonal IgG1 antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis and reducing tumor blood supply. It is FDA-approved for multiple cancers including metastatic colorectal, lung, ovarian, kidney, cervical cancers, and more. Bevacizumab is typically administered intravenously and is a key agent in anti-angiogenic therapy[1][2][3][4][5][6][7][8][9][10]. - **Adebrelimab**: A monoclonal antibody targeting programmed death ligand 1 (PD-L1), functioning as an **immune checkpoint inhibitor**. Adebrelimab is under investigation and has shown promise in clinical trials for several solid tumors, particularly in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It enhances anti-tumor immune responses by blocking PD-L1 from binding to PD-1[No direct citation in provided results, expert knowledge]. This combination represents a **triplet regimen** incorporating cytotoxic chemotherapy, anti-angiogenic targeted therapy, and immunotherapy (checkpoint inhibition).